All In Biotech

Drug Trial Radar · NCT04140500

Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors

An Open Label, Multicenter, Dose Escalation, Phase 1 Study to Evaluate Safety/Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Anti Tumor Activity of RO7247669, a PD1-LAG3 Bispecific Antibody, in Patients With Advanced and/or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

170

Actual

Start

Nov 11, 2019

Primary completion

Jun 30, 2027

Study completion Jun 30, 2027

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
First posted
Oct 28, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human, open-label, multicenter, Phase I multiple-ascending dose (MAD) study of RO7247669, an anti PD-1 (programmed death-1) and LAG-3 (Lymphocyte-activation gene 3) bispecific antibody, for participants with advanced and/or metastatic solid tumors. This study aims to establish the maximum tolerated dose (MTD) and/or define the recommended phase 2 dose (RP2D) based on the safety, tolerability, pharmacokinetic (PK) and/or pharmacodynamic (PD) profile of RO7247669, and to evaluate preliminary anti-tumor activity in participants with solid tumors. An expansion part of the study is planned to enroll tumor-specific cohorts to evaluate anti-tumor activity of the MTD and/or RP2D of RO7247669 and to confirm safety and tolerability in participants with selected tumor types.

Conditions

  • Solid Tumors
  • Metastatic Melanoma
  • Non-small Cell Lung Cancer
  • Esophageal Squamous Cell Carcinoma

Interventions

  • RO7247669Drug

    Participants will receive intravenous (IV) RO7247669 at different doses either every 2 weeks (Q2W) or every 3 weeks (Q3W)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Percentage of Participants with Dose-Limiting Toxicities (DLTs)Time frame: Days 1-21 (Q2W dosing) or Days 1-28 (Q3W dosing) of Cycle 1
  2. Part A: Percentage of Participants with Adverse EventsTime frame: Baseline through the end of study (up to 24 months)
  3. Part B: Objective Response Rate (ORR)Time frame: Up to 24 months
  4. Part B: Disease Control Rate (DCR), Defined as ORR + Stable Disease Rate (SDR)Time frame: Up to 24 months
  5. Part B: Duration of Response (DOR)Time frame: Up to 24 months
  6. Part B: Progression-free Survival (PFS), Defined as the Time from the First Study Treatment to the First Occurrence of Progression per Investigator Assessment or Death from any Cause, Whichever Occurs FirstTime frame: Up to 24 months

Locations

25 sites in 9 countries. Site status is shown where the registry gives one.

  • Rigshospitalet

    København Ø, Denmark

  • Odense Universitetshospital, Onkologisk Afdeling R

    Odense C, Denmark

  • LLC Arensia Explorer Medicine

    Tbilisi, Georgia

  • Hadassah University Hospital - Ein Kerem

    Jerusaelm, Israel

  • Rabin MC

    Petah Tikva, Israel

  • Chaim Sheba medical center, Oncology division

    Ramat Gan, Israel

  • Hospital Civil de Guadalajara Fray Antonio Alcalde

    Guadalajara, Jalisco, Mexico

  • Inst. Nacional de Cancerología

    Mexico City, Mexico CITY (federal District), Mexico

  • Consultorio Médico Jordi Guzmán Casta

    Querétaro City, Querétaro, Mexico

  • National University Hospital

    Singapore, Singapore

  • National Cancer Centre

    Singapore, Singapore

  • Seoul National University Bundang Hospital

    Seongnam-si, South Korea

  • Severance Hospital, Yonsei University Health System

    Seoul, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Vall d?Hebron Institute of Oncology (VHIO), Barcelona

    Barcelona, Spain

  • Clinica Universidad de Navarra Madrid

    Madrid, Spain

  • START Madrid-FJD, Hospital Fundacion Jimenez Diaz

    Madrid, Spain

  • START Madrid. Centro Integral Oncologico Clara Campal

    Madrid, Spain

  • Clinica Universitaria de Navarra

    Pamplona, Navarre, Spain

  • Adana City Hospital, Medical Oncology

    Adana, Turkey (Türkiye)

  • Ankara City Hospital

    Ankara, Turkey (Türkiye)

  • Hacettepe Uni Medical Faculty Hospital

    Sihhiye/Ankara, Turkey (Türkiye)

  • Ankara Abdurrahman Yurtaslan Oncology Training and Research Hospital Phase 1 Center

    Yen?mahalle, Turkey (Türkiye)

  • Queen Elizabeth Hospital

    Birmingham, United Kingdom

  • Christie Hospital NHS Trust

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.